However, the tumor volume of H19 shRNA/Dox group was smaller than that of NC shRNA/Dox group, and significant difference in the tumor volume was observed between the two group (Figure 5(a)), suggesting that targeting H19 expression sensitizes breast cancer cells to Dox in vivo. The gene discussed is H19; the disease is breast cancer.